Vascepa, also known as icosapent ethyl, is a medication used to reduce triglyceride levels in the blood. It has been approved by the FDA for the treatment of high triglycerides since 2012 [1][DrugPatentWatch.com 2022]. However, the approval process for its other indications is ongoing.

In 2020, the FDA approved Vascepa for reducing the risk of cardiovascular events in adults with established cardiovascular disease and elevated triglycerides, but the decision was appealed in court [2]. In February 2023, the FDA approved the new indication based on the REDUCE-IT trial results [3].

As for the ongoing approvals, Vascepa's makers, Amarin, have been working on expanding the medication's indications to treat different types of cardiovascular disease. For example, in 2022, a Phase III trial assessing Vascepa's efficacy in treating diabetic patients with high triglycerides was announced [4].

Amarin has also been seeking approval for a generic version of Vascepa, which would make the medication more affordable for patients. However, drug manufacturers have been involved in patent disputes over the medication's formulation. According to DrugPatentWatch.com, the patents for Vascepa are expected to begin expiring in 2024 [5].

As the approvals process continues, patients and healthcare providers can track the progress of Vascepa's indications and potential generic alternatives on websites like DrugPatentWatch.com.

Sources:
[1] FDA. (2012). FDA approves Vascepa (icosapent ethyl) for high triglycerides.
[2] Reuters - Breaking Views. Court Ruling on FDA Vascepa Approval.
[3] FDA. (2023). FDA approves Vascepa to reduce cardiovascular risk in adults with established cardiovascular disease and elevated triglycerides.
[4] News Medical Life Sciences. (2022). Efficacy of icosapent ethyl in diabetic patients with high triglycerides: a Phase III clinical trial.
[5] DrugPatentWatch.com. (2022). Vascepa/icosapent ethyl.